TREACE MEDICAL CONCEPTS, INC. (TMCI): Price and Financial Metrics
TMCI Price/Volume Stats
| Current price | $13.38 | 52-week high | $27.97 |
| Prev. close | $13.43 | 52-week low | $13.27 |
| Day low | $13.28 | Volume | 495,000 |
| Day high | $13.65 | Avg. volume | 419,569 |
| 50-day MA | $18.01 | Dividend yield | N/A |
| 200-day MA | $22.86 | Market Cap | 823.47M |
TMCI Stock Price Chart Interactive Chart >
TMCI POWR Grades
- Sentiment is the dimension where TMCI ranks best; there it ranks ahead of 70.27% of US stocks.
- The strongest trend for TMCI is in Value, which has been heading up over the past 179 days.
- TMCI's current lowest rank is in the Stability metric (where it is better than 13.97% of US stocks).
TMCI Stock Summary
- TMCI's went public 2.41 years ago, making it older than just 7.01% of listed US stocks we're tracking.
- TMCI's price/sales ratio is 5.35; that's higher than the P/S ratio of 81.11% of US stocks.
- Revenue growth over the past 12 months for TREACE MEDICAL CONCEPTS INC comes in at 46.37%, a number that bests 87.96% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to TREACE MEDICAL CONCEPTS INC are EVER, AMRN, TREE, SNOA, and SPWR.
- Visit TMCI's SEC page to see the company's official filings. To visit the company's web site, go to www.treace.com.
TMCI Valuation Summary
- In comparison to the median Healthcare stock, TMCI's EV/EBIT ratio is 306.45% lower, now standing at -25.6.
- Over the past 29 months, TMCI's price/sales ratio has gone down 17.2.
Below are key valuation metrics over time for TMCI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TMCI | 2023-09-18 | 5.3 | 6.0 | -21.1 | -25.6 |
| TMCI | 2023-09-15 | 5.3 | 5.9 | -20.9 | -25.3 |
| TMCI | 2023-09-14 | 5.6 | 6.3 | -22.2 | -26.8 |
| TMCI | 2023-09-13 | 5.7 | 6.4 | -22.6 | -27.3 |
| TMCI | 2023-09-12 | 5.6 | 6.2 | -22.2 | -26.7 |
| TMCI | 2023-09-11 | 5.2 | 5.8 | -20.7 | -25.0 |
TMCI Price Target
For more insight on analysts targets of TMCI, see our TMCI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $35.00 | Average Broker Recommendation | 1.38 (Strong Buy) |
TREACE MEDICAL CONCEPTS, INC. (TMCI) Company Bio
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest TMCI News From Around the Web
Below are the latest news stories about TREACE MEDICAL CONCEPTS INC that investors may wish to consider to help them evaluate TMCI as an investment opportunity.
Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023PONTE VEDRA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ clinical study at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Me |
Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. PatentPONTE VEDRA, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, is pleased to announce the United States Patent and Trademark Office’s (USPTO) forthcoming issuance of U.S. Patent No. 11,771,467, to publish on October 3, 2023 (the ‘467 Patent). “Our |
Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related ProceduresFurther Expands Market Opportunity to Include Hammertoe Correction Company Receives 510(k) Clearance for Second-Generation SpeedPlate™ Implant Fixation Platform Ahead of Full Market Launch in Fourth Quarter of 2023 PONTE VEDRA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D |
Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare ConferencePONTE VEDRA, Fla., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the 21st Annual Morgan Stanley Global Heal |
Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, MarketingPONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace’s marketing effo |
TMCI Price Returns
| 1-mo | -13.06% |
| 3-mo | -44.04% |
| 6-mo | -47.63% |
| 1-year | -40.95% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -41.80% |
| 2022 | 23.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...